EBITDA společnosti Zynex
Jaká je hodnota metriky EBITDA společnosti Zynex?
Hodnota metriky EBITDA společnosti Zynex, Inc. je $27.296M
Jaká je definice metriky EBITDA?
EBITDA je zisk před odečtením úroků, daní, odpisů a amortizací udávající operační výkonnost společnosti.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA společností v sektoru Health Care sektor na HKSE ve srovnání se společností Zynex
Čemu se věnuje společnost Zynex?
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Firmy s metrikou ebitda podobnou společnosti Zynex
- Hodnota metriky EBITDA společnosti BBX Capital je $27.168M
- Hodnota metriky EBITDA společnosti Sword SE je €27.170M
- Hodnota metriky EBITDA společnosti MiX Telematics Ltd je $27.174M
- Hodnota metriky EBITDA společnosti Andrews Sykes plc je £27.198M
- Hodnota metriky EBITDA společnosti Premier Miton plc je £27.199M
- Hodnota metriky EBITDA společnosti Computer Modelling je CAD$27.215M
- Hodnota metriky EBITDA společnosti Zynex je $27.296M
- Hodnota metriky EBITDA společnosti Antioquia Gold je CAD$27.336M
- Hodnota metriky EBITDA společnosti C & F Corp je $27.338M
- Hodnota metriky EBITDA společnosti Tongfang Kontafarma je HKD$27.343M
- Hodnota metriky EBITDA společnosti Artivion Inc je $27.349M
- Hodnota metriky EBITDA společnosti Zhong Hua International je HKD$27.350M
- Hodnota metriky EBITDA společnosti IM+ Capitals je ₨27.360M